Oral contraceptives and antithrombin III: variations by dosage and ABO blood group.
A randomized clinical trial of oral contraceptives evaluated 67 women on a regimen of 50 micrograms ethinyl estradiol and 1.0 mg norethindrone, 61 women on a regimen of 35 micrograms ethinyl estradiol and 1.0 mg norethindrone, and 64 women on a regimen of 35 micrograms ethinyl estradiol and 0.5 mg norethindrone. ABO blood group type was determined in all women. At baseline and at 3, 6, and 9 months, plasma antithrombin III levels, by both an immunologic and an activity method, and selected plasma levels of the contraceptive steroids were measured. Antithrombin III levels for all oral contraceptive groups combined decreased from baseline by 19.7% and 28.8% for the immunologic and activity methods, respectively. Analysis of interrelationships among antithrombin III by activity method, oral contraceptive type, and ABO blood group showed larger declines in antithrombin III for type O women using the highest estrogen dose preparation (31.6%) and for non-type O women using the lowest progestin dose preparation (38.9%). Plasma levels of contraceptive steroids also were related to changes in the most extreme levels of antithrombin III.
Burkman
R T
RT
Department of Gynecology-Obstetrics, Henry Ford Hospital, Detroit, MI 48202.
Bell
W R
WR
Zacur
H A
HA
Kimball
A W
AW
D000017:ABO Blood-Group System; D000328:Adult; D000990:Antithrombin III / Q000032:analysis*; D003276:Contraceptives, Oral / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D007158:Immunologic Techniques; D009640:Norethindrone / Q000494:pharmacology
D000017:ABO Blood-Group System; D003276:Contraceptives, Oral; D004997:Ethinyl Estradiol; D000990:Antithrombin III; D009640:Norethindrone